Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial.

Kenneth W MahaffeyKatherine R TuttleMustafa AriciFlorian M M BaeresGeorge BakrisDavid M CharytanDavid Z I CherneyGil CherninRicardo Correa-RotterJanusz GumprechtThomas IdornGiuseppe PuglieseIda Kirstine Bull RasmussenSøren RasmussenEllen BurgessEkaterina SokarevaJohannes F E MannVlado PerkovicRichard E Pratley

Published in: European heart journal (2024)

Semaglutide significantly reduced the risk of CV death/MI/stroke regardless of baseline CKD severity in participants with T2D.

Keyphrases

chronic kidney disease
type diabetes
end stage renal disease
atrial fibrillation
clinical trial
study protocol
phase iii
cardiovascular disease
glycemic control
phase ii
randomized controlled trial
insulin resistance
metabolic syndrome
skeletal muscle